Evidence map›Paper›PMID 42159708›Full record

ReviewApplied microbiology and biotechnology2026

Application of clearance strategies for extractables and leachables and advances in process modeling.

Armin Hauk, Maximilian Bossong, Ina Pahl, Tanja Verena Maier, Roberto Menzel

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Armin HaukSartorius Stedim Biotech GmbH, 37079, Göttingen, Germany. armin.hauk@sartorius.com.
Maximilian BossongSartorius Stedim Biotech GmbH, 37079, Göttingen, Germany.
Ina PahlSartorius Stedim Biotech GmbH, 37079, Göttingen, Germany.
Tanja Verena MaierSartorius Stedim Biotech GmbH, 37079, Göttingen, Germany.
Roberto MenzelSartorius Stedim Biotech GmbH, 37079, Göttingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-use devices made from plastic materials and used in the manufacturing of pharmaceutical products were identified as sources of extractables and potentially process equipment-related leachables (PERLs), which may interfere with process performance and product quality. In this contribution, the sinks of PERLs in biopharmaceutical processes are explored and the underlying physical-chemical mechanisms are discussed. This includes an overview of studies on leachable clearance with ultrafiltration/diafiltration operations (UF/DF) and chromatographic steps, filter rinsing, and adsorption. Literature reveals that dilution and phase separation are the main drivers for reducing PERL exposure along a process. Integrating extractables release and established physical processes of dynamic dilution and phase separation allows to set up and populate mathematical models which can predict the fate of PERLs in batch and continuous bioprocessing. Integrating the fate of PERLs improves process understanding, supports process qualification studies, and, ultimately, strengthens the patient safety assessment. KEY POINTS: • It is possible to demonstrate that biopharmaceutical processes can significantly reduce PERLs. • Various process operation steps are identified as sinks for PERLs, and the fate of PERLs is predictable with simple mathematical models. • Using PERL exposure models improves process understanding and enhances the safety assessments for single-use devices used in bioprocessing.

Indexed as

Drug ContaminationTechnology, PharmaceuticalAdsorptionChromatographyFiltrationModels, TheoreticalPharmaceutical PreparationsUltrafiltrationPharmaceutical PreparationsBiopharmaceutical manufacturingExtractablesFate of PERLsModelingPERL exposureProcess equipment-related leachablesSafety assessment

Identifiers

PMID42159708
PMCPMC13190347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.